Aandeel 61Y MARINUS PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Marinus Pharmaceuticals, Inc. BOERSE MUENCHEN

Aandelen

61Y

US56854Q2003

Beurs gesloten - BOERSE MUENCHEN
Andere beurzen
 21:43:26 19-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
1,31 EUR 0,00% Intraday-grafiek van Marinus Pharmaceuticals, Inc. -5,76% -86,83%
17/06 Sectorupdate: Gezondheidszorgaandelen dalen premarket maandag MT
17/06 Top premarket dalers MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
Sector Update: Health Care Stocks Decline Premarket Monday
Top Premarket Decliners
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
Marinus Pharmaceuticals : Corporate Overview Slide Deck
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
Marinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action Lawsuit
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors
Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors
The Law Offices of Frank R. Cruz Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers MRNS
  4. Koers 61Y
  5. Nieuws Marinus Pharmaceuticals, Inc.
  6. Andere talen